Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-07-2023 | Ibrutinib | Case report

Ibrutinib

Transaminitis, neutropenia and granulomatous inflammation: 3 case reports

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Hampel PJ, et al. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. British Journal of Haematology 199 : 239-244, No. 2, Oct 2022. Available from: URL: http://doi.org/10.1111/bjh.18357 Hampel PJ, et al. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. British Journal of Haematology 199 : 239-244, No. 2, Oct 2022. Available from: URL: http://​doi.​org/​10.​1111/​bjh.​18357
Metadata
Title
Ibrutinib
Transaminitis, neutropenia and granulomatous inflammation: 3 case reports
Publication date
01-07-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-43205-9

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Gemcitabine

Case report

BCG

Case report

Mercaptopurine